Mabthera® (Rituximab) for the Treatment of Severe Granulomatosis With Polyangiitis (Gpa) and Microscopic Polyangiitis (Mpa) - A Cost-Utility Model for the United Kingdom.

Autor:	Harland, D.1, Naisbett-Groet, B.1, Chang, S.2, Sungher, D.K.3, Sawyer, L.2, Diamantopoulos, A.4
Zdroj:	Value in Health. Nov2014, Vol. 17 Issue 7, pA382-A382. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect